Usefulness of evaluation of soluble fragment cytokeratln 18, carclnoembryonlc antigen and gastrointestinal carcinoma-associated antigen in diagnostic of patients with colorectal cancer;Przydatność oznaczeń rozpuszczalnego fragmentu cytokeratyny 18., antygenu karcynoembrionalnego oraz mucynopochodnego antygenu (CA 19-9) w diagnostyce chorych na raka okrȩżnicy i od by tn icy

Polski Merkuriusz Lekarski

Volumn 29, Issue 170, 2010, Pages 128-130

  Partyka, Robert ^a   Sandelewski, Artur ^a   Łobejko, Iwona ^b   Kocot, Jacek ^a   Jałowiecki, Przemysław ^a   Kokocińska, Danuta ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b St Barbara's Voivodship Specialistic   (Poland)

Author keywords

CA 19 9; CEA; Colorectal cancer; Tissue polypeptide specific antigen (TPS)

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 18; PEPTIDE; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

COLORECTAL TUMOR; HUMAN; IMMUNOLOGICAL PROCEDURES; METABOLISM; PROGNOSIS; REVIEW;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; IMMUNOLOGIC TESTS; KERATIN-18; PEPTIDES; PROGNOSIS;

EID: 77956901472     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Abel Rahman E.M., El Goniny AA, Farouk S.: Prognostic value of preoperative assessment of sewm carxano-embryonic antigen and carbohydrate antigen 19-9 levels in colorectal carcinoma. Qatar Med. J., 2007,16, 2,12-15.
2. Bjorklund B., Bjorklund V.: Biochemishce und morphologlsche Grundlagen von TPA: Fortschritte in Richtung auf einen allgemlenen Marker fur aktive Tumoren durch monoklonale kertierung. In: Tumormarkersystem CEA-TPA. Tumor Diagnostik (eds Luthgens M., Schlegel G., Leonberg). 1987,14-29.
3. Boardman L, Karnes W.E. jr.: Epidemiology and etiology. Section IV: colon and rectum: neoplasms in: Surgery of colon and rectum (eds Don Nickolls L.J., Dosois R.R.). New York Churchill, Livingstone., 1997,335-348.
4. Carpelan-Holmstrom M., Louhimo J., Stenman U.-H. i wsp.: CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta In the diagnosis of recurrent colorectal cancer. Tumor biology, 2004, 25, 5-6, 228-234.
5. Carpelan-Holmstrom M., Louhimo J., Stenman U.H. i wsp.: Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology, 2004, 66, 4, 296-302.
6. Duffy M.J., van Dalen A., Haglund C. i wsp.: Clinical utility of biochemical markers In colorectal cancer European Group on Tumor Manners (EGTM) guidelines. Eur. J. Cancer, 2003, 39: 718-727.
7. Eche N.: Markers of digestive cancers: Colon, rectum, pancreas, liver. Immuno-Analyse et Biologic Specialise, 2004, 19, 5, 279-285.
8. Filella X., Molina M.D., Gran M.D. i wsp.: Prognostic value of CA 19-9 in colorectal cancer. Ann. Surg., 1992, 210, 55-59.
9. Gold P., Freedman S.O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 1965, 122: 467.
10. Gonzalez-Quintela A, Mella C, Abdulkader I i wsp.: Serum levels of tissue polypeptide specific antigen are correlated with hepatocyte cytoke-ratin expression In alcoholic liver disease. Alcohol Clin. Exp. Res., 2004, 28, 9, 1413-1418.
11. Gonzalez-Quintela A, Mella C, Perez LF i wsp.: Increased serum tissue polypeptide specific antigen (TPS) in alcoholics: a possible marker of alcoholic hepatitis. Alcohol Clin Exp Res., 2000, 24, 8, 1222-1226.
12. Grotowski M.: Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer Pol Merk Lek., 2002, 12, 67, 77-80.
13. Kobayashi T., Sawa H., Morikawa J. i wsp.: Bax Induction activates apop-totic cascade via mitochondria cytochrome c release and Bax of the expression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer. Jpn. J. Cancer Res., 2000, 91, 12, 1264-1268.
14. Kokocińska D.: Przydatność oznaczeń markerów nowotworowych w chi-rurgii ukladu pokarmowego. Chir. Pol., 1999, 1, 2, 101-115.
15. Luksaite R., Sauer-Eppel H., Oremek G.M.: Value of biomarkers in diagnosis of gastric carcinoma. Clin. Exp. Medical Letters, 2009, 50, 1, 1-4.
16. Mishaeli M., Klein B., Sadikov E. i wsp.: Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res., 1998, 18: 2101-2106.
17. Nowacki M.P., Jaskóta K., Olȩdzki J.: Wspólczesne zasady leczenia skojarzonego raków okrȩżnicy, odbytnicy I odbytu. Nowotwory, 1998, 48, 1011-1030.
18. Plebani M., De Maoll M., Basso D. i wsp.: Serum tumor markers In colorectal cancer staging, granding, and follow-up. J. Surg. Oncol., 1996 Aug, 62, 4, 239-244.
19. Rydlander L., Zieglar E., Bergman T. i wsp.: Molecular characteristic of a tissue-polyleltlde-specific-antigen epitope and its relationship to human cytokertin 18. Eur. J. Biochem., 1996, 241, 309-314.
20. Sandelewskl A., Kokocinska D., Partyka R. i wsp.: Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cyto-keratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer. Pol. Merk. Lek., 2005, 18, 108, 647-650.
21. Slamenik M.: The most frequently exploited tumor markers. Prakticky Lekar., 2004, 84, 11, 658-661.
22. Treska V., Topolcan O., Stanislav K. i wsp. Preoperative tumor markers as prognostic factors of colorectal liver metastases. Hepato-Gastroenterology, 2009, 56, 90, 317-320.
23. Weissenberger C, Von Plehn G., Otto F. i wsp.: Adjuvant radiochemo-therapy of stage II and III rectal adenocarcinoma: Role of CEA and CA 19-9. Anticancer Res., 2005, 25, 3, 1787-1793.